1
Choose the CONTOUR®NEXT Portfolio Blood Glucose Meter that works best for you.
CONTOUR®NEXT EZ
CONTOUR®NEXT ONE
2
Write a Medicare Part B prescription for CONTOUR®NEXT.
To avoid callbacks and ensure your patient receives the CONTOUR®NEXT Brand:
Remember, CONTOUR®NEXT Test Strips are always covered under Medicare Part B!*
3
Direct your patients to their pharmacy for fulfillment of their CONTOUR®NEXT prescription.
This is for informational purposes only. Please visit www.medicare.gov to learn more about Medicare plans and coverage.
Test strips are covered when medically necessary and prescribed by a physician. Medicare will reimburse either 80% of the Medicare Fee Schedule or the actual charges, whichever is less.
More questions about Medicare?
Learn more about Medicare plans and coverage at: https://www.medicare.gov/pubs/11022-Medicare-Diabetes-Coverage.pdf
This is for informational purposes only. Please visit www.medicare.gov to learn more about Medicare plans and coverage.
CONTOUR® NEXT Test Strips
For non-insulin treated patients
For insulin treated patients
Important note:
Medicare allows additional test strips and lancets if deemed medically necessary. See LMN Matters SE1008 for more information: https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/SE1008.pdf
If your patients have any difficulty in obtaining their CONTOUR®NEXT test strips please call us (1-800-348-8100) and we will help them find a Medicare supplier who will provide them with CONTOUR®NEXT test strips.
To find a supplier that’s enrolled in Medicare, visit www.medicare.gov/supplier or call 1-800-MEDICARE (1-800-633-4227) .
†10% applies to glucose levels ≥100 mg/dL. In multiple clinical trials examined by Bernstein et al., the CONTOUR®NEXT meter portfolio delivered at least 95% of results within 10% of the laboratory reference value for blood glucose concentrations ≥100 mg/dL and within ±10 mg/dL of the laboratory reference value for blood glucose concentrations <100 mg/dL.
‡ ±8.4% applies to values ≥100mg/dL. An ad hoc analysis demonstrated 95% of results fell within ±8.4 mg/dL or ±8.4% of the laboratory reference values for glucose concentrations <100 mg/dL or ≥100 mg/dL, respectively, when tested via subject-obtained capillary fingertip results (patients with diabetes).
*Not a guarantee of coverage and payment. A doctor’s prescription is required for Medicare coverage and patients must meet Medicare eligibility coverage criteria. Coverage and payment may be subject to coinsurance, deductible and patient eligibility requirements. Visit http://www.medicare.gov to learn more about Medicare plans and coverage.
References: 1. Bernstein, R. et al. A new test strip technology platform for self-monitoring of blood glucose. Journal of Diabetes Science and Technology. 2013; 7(5):1386-1399. 2. Christiansen, M. et al. A New, Wireless-enabled Blood Glucose Monitoring System That Links to a Smart Mobile Device: Accuracy and User Performance Evaluation. Journal of Diabetes Science and Technology. 2017, Vol. 11(3) 567-573.3. Ascensia Diabetes Care. Data on File. Market Research, Hall & Partners, conducted online April/May 2015
The information brought to you by Ascensia Diabetes Care US Inc. provides general information and is not a guarantee of coverage or payment (partial or full), and is not intended as medical advice, diagnosis or treatment. Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures.
©2020 Ascensia Diabetes Care US Inc. All rights reserved.